UPDATE: Jefferies & Company Reiterates Buy Rating, Lowers PT on NxStage Medical
In a report published Friday, Jefferies & Company reiterated its Buy rating on NxStage Medical (NASDAQ: NXTM), but lowered its price target from $21.00 to $16.00.
Jefferies noted, “NXTM posted a decent 3Q. Overall HHD grew 17% but US HHD growth again decelerated (+12%) and will remain in check under the current reimbursement environment. The company outlined an increasing number of pipeline opportunities and while achieving increased reimbursement will take time, the substantial long-term HHD opportunity supports our Buy rating.”
NxStage Medical closed on Thursday at $10.61.
Latest Ratings for NXTM
|Mar 2016||Piper Jaffray||Assumes||Overweight|
|Dec 2015||BTIG Research||Initiates Coverage on||Buy|
|Feb 2015||Canaccord Genuity||Maintains||Buy|
© 2016 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.